13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001931118
Total reported value
$158.4M
$158.4M
37 檔
40.8%
The Q1 2024 SEC filing reveals that Superstring Capital Management LP held a total portfolio value of $158.4M, covering 37 public equity positions.
During Q1 2024, Superstring Capital Management LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CYTK | Cytokinetics Inc | Stock-Healthcare | 12.93% | — | +57.04% | |
| 2 | NKTX | Nkarta Inc | Stock-Other | 8.50% | — | +242.33% | |
| 3 | ETNBGBP | 89bio Inc | Stock-Other | 7.24% | — | -7.85% | |
| 4 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 7.23% | — | +71.33% | |
| 5 | SVRA | Savara Inc | Stock-Other | 6.80% | -2.39% | +153.62% | |
| 6 | IDYA | Ideaya Biosciences Inc | Stock-Other | 6.30% | — | -13.62% | |
| 7 | FATE | Fate Therapeutics Inc | Stock-Other | 4.47% | — | +8.57% | |
| 8 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 3.82% | — | -7.89% | |
| 9 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 3.70% | +0.57% | NEW | |
| 10 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 3.47% | — | -36.24% | |
| 11 | MRNS* | Marinus Pharmaceuticals Inc | Stock-Other | 3.38% | — | +22.30% | |
| 12 | CABA | Cabaletta Bio Inc | Stock-Other | 3.28% | +0.15% | — | |
| 13 | URGN | UroGen Pharma Ltd. | Stock-Other | 2.86% | -0.53% | +12.86% | |
| 14 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 2.76% | — | +109.11% | |
| 15 | ✓ | Stock-Other | 2.16% | — | — | ||
| 16 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.97% | — | — | |
| 17 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.93% | +6.98% | +126.26% | |
| 18 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.87% | — | — | |
| 19 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.62% | — | — | |
| 20 | ALLO | Allogene Therapeutics Inc | Stock-Other | 1.54% | — | +134.68% | |
| 21 | KROS | Keros Therapeutics Inc | Stock-Other | 1.48% | — | -54.68% | |
| 22 | PYXS | Pyxis Oncology Inc | Stock-Other | 1.39% | — | — | |
| 23 | ASND | Ascendis Pharma A/S | Stock-Other | 1.27% | — | — | |
| 24 | PEPG | Pepgen Inc | Stock-Other | 1.11% | — | — | |
| 25 | TRML | Tourmaline Bio Inc | Stock-Other | 1.06% | — | — | |
| 26 | ALLKGUSD | Allakos Inc | Stock-Other | 1.03% | — | — | |
| 27 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.98% | — | — | |
| 28 | ANNX | Annexon Inc | Stock-Other | 0.74% | — | — | |
| 29 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.62% | — | — | |
| 30 | LYRAGBP | Lyra Therapeutics Inc | Stock-Other | 0.60% | — | — | |
| 31 | ✓ | Inozyme Pharma Inc | Stock-Other | 0.57% | — | -9.04% | |
| 32 | AUPH | Aurinia Pharmaceuticals Inc | Stock-Other | 0.33% | — | — | |
| 33 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.25% | — | — | |
| 34 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 0.24% | — | — | |
| 35 | SPRU | Spruce Power Holding Corporation | Stock-Other | 0.23% | — | +270.52% | |
| 36 | ✓ | Stock-Other | 0.14% | — | — | ||
| 37 | SY | So-young International-adr | Stock-Other | 0.13% | — | -77.04% |
According to official SEC Form 13F filings, Superstring Capital Management LP reported a total U.S. public equity portfolio value of $158.4M across 37 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CYTK, NKTX, ETNBGBP) accounted for 40.8% of total reported equity market value during Q1 2024.
During Q1 2024, Superstring Capital Management LP's top holdings by market value included CYTK (12.9%)、NKTX (8.5%)、ETNBGBP (7.2%). The largest single position, CYTK, represented 12.9% of total portfolio value.
In Q1 2024, Superstring Capital Management LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.